Se trata de un ensayo clínico multicéntrico, prospectivo, de fase II, aleatorizado, doble ciego con control simulado(placebo) para evaluar la eficacia y la seguridad del condicionamiento isquémico remoto (RIC) en pacientes con linfoma no Hodgkin (LNH) que vayan a recibir tratamiento quimioterápico con antraciclinas (al menos 5 ciclos).

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions